IP Library Granted Patent US 12,480,105
Granted Patent B2
US 12,480,105 · App. 17/254,376 · Granted Nov 25, 2025

High temperature resistant reverse transcriptase mutants and use thereof

Inventors: Xiwen Jiang (Guangdong, CN); Aishan Liu (Guangdong, CN); Zhouquan Wang (Guangdong, CN); Sangsang Zheng (Guangdong, CN); Jiguang Zhao (Guangdong, CN); Xianlan Lian (Guangdong, CN); Xiaocheng Xie (Guangdong, CN); Xuelan Lu (Guangdong, CN); Wei Zhang (Guangdong, CN); Haojian Xu (Guangdong, CN); Zhikeng Fang (Guangdong, CN); Zhijian Wu (Guangdong, CN)
Assignee: Daan Gene Co., Ltd.
C12N9/1276C12N15/1096C12Y207/07049
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,480,105
App. No.
17/254,376
Granted
Nov 25, 2025
Kind
B2
Abstract

The present invention provides a high temperature resistant reverse transcriptase mutant and its use. In particular, the present invention constructs a reverse transcriptase (M-MLV) mutant library, and the mutants with improved thermostability and higher amplification efficiency are finally screened out by stepwise screening. Under high temperature conditions, the reverse transcription efficiency of the reverse transcriptase mutant of the present invention is greatly improved compared to the wild type.

Claims (8)

1 . A reverse transcriptase mutant having mutation(s) at amino acid residue(s) selected from the group consisting of: 313, 446, and 583,

wherein the amino acid residues are numbered according to SEQ ID NO: 1, a wild-type murine leukemia virus reverse transcriptase (M-MLV), and

wherein a reverse transcription efficiency of the reverse transcriptase mutant is higher compared to the wild-type murine leukemia virus reverse transcriptase.

2 . The reverse transcriptase mutant of claim 1 , wherein the amino acid residue 446 is mutated to Cys, the amino acid residue 313 is mutated to Gln, and the amino acid residue 583 is mutated to Asn.

3 . The reverse transcriptase mutant of claim 1 , wherein

the reverse transcriptase mutant has mutations at the amino acid residues 583 and 446, wherein the amino acid residue 583 is mutated to Asn, and the amino acid residue 446 is mutated to Cys, or the reverse transcriptase mutant has mutations at the amino acid residues 313 and 446, wherein the amino acid residue 313 is mutated to Gln, and the amino acid residue 446 is mutated to Cys, or the reverse transcriptase mutant has mutations at the amino acid residues 313, 583 and 446, and wherein the amino acid residue 313 is mutated to Gln, the amino acid residue 583 is mutated to Asn, and the amino acid residue 446 is mutated to Cys.

4 . A method for RNA reverse transcription comprising:

providing an RNA-containing sample; and performing a reverse transcription reaction of the RNA-containing sample with the reverse transcriptase mutant of claim 1 .

Assignments (2)
CHANGE OF NAME Recorded Aug 6, 2021
From: DAAN GENE CO., LTD. OF SUN YAT-SEN UNIVERSITY
To: DAAN GENE CO., LTD.
Reel/Frame 057115/0835 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2020
From: JIANG, XIWEN; LIU, AISHAN; WANG, ZHOUQUAN; ZHENG, SANGSANG; ZHAO, JIGUANG; LIAN, XIANLAN; XIE, XIAOCHENG; LU, XUELAN; ZHANG, WEI; XU, HAOJIAN; FANG, ZHIKENG; WU, ZHIJIAN
To: DAAN GENE CO., LTD. OF SUN YAT-SEN UNIVERSITY
Reel/Frame 054706/0710 →
Priority Claims (1)
CN 201911105358.X · Nov 13, 2019 · national
Continuity (1)
Related Publication 20240254460A1 · Aug 1, 2024
References Cited (18)
US 20050232934A1 · Chen et al. · 2005 [cited by applicant]
US 20240254460A1 · Jiang · 2024 [cited by examiner]
CA 2617790A1 · 2007 [cited by applicant]
CN 1807605A · 2006 [cited by applicant]
CN 102057039A · 2011 [cited by applicant]
CN 106164261A · 2016 [cited by applicant]
CN 110291196A · 2019 [cited by applicant]
WO 2007022045A2 · 2007 [cited by applicant]
WO 2012020759A1 · 2013 [cited by applicant]
WO 2015112767A2 · 2015 [cited by applicant]
WO 2018057909A1 · 2018 [cited by applicant]
WO 2018110595A1 · 2019 [cited by applicant]
Yasukawa et al., “Increase in thermal stability of Moloney murine leukaemia virus reverse transcriptase by site-directed mutagenesis”, Journal of Biotechnology, first published Sep. 29, 2010, pp. 299-306. [cited by applicant]
Arezi et al., “Novel mutations in Moloney Murine Leukemia Virus reverse transcriptase increase thermostability through tighter binding to template-primer”, Nucleic Acids Research, first published Dec. 4, 2008, pp. 473-4… [cited by applicant]
The extended European search report issued in European application No. 20824054.9, dated Oct. 31, 2022, 9 pages provided. [cited by applicant]
International Search Report and Written Opinion issued in PCT/CN2020/128639, dated Jan. 28, 2021, 21 pages provided, with English translation. [cited by applicant]
Aurimas Baranauskas et al., “Generation and characterization of new highly thermostable and processive M-MuLV reverse transcriptase variants”, Protein Engineering, Design & Selection, vol. 25, No. 10, Jun. 12, 2012, cit… [cited by applicant]
International Preliminary Report on Patentability issued in PCT/CN2020/128639, issued May 17, 2022, with English translation, 5 pages provided. [cited by applicant]